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Abstract 
Complex regional pain syndrome (CRPS) is a post-traumatic pain condition with an 
incompletely understood pathophysiological basis.  Here, we have examined the cellular basis of 
pain in CRPS using behavioral and electrophysiological methods in mice treated with IgG from 
CRPS patients, in combination with a paw incision. Mice were subjected to a hind paw skin-
muscle incision alone, or in combination with administration of IgG purified from either healthy 
control subjects (HC) or patients with persistent CRPS. Nociceptive function was examined 
behaviorally in vivo, and electrophysiologically in vitro using skin-nerve preparations to study 
the major classes of mechanosensitive single units. Administration of IgG from CRPS patients 
exacerbated and prolonged the post-surgical hypersensitivity to noxious mechanical, cold and 
heat stimulation, but did not influence tactile sensitivity following a paw incision. Studies of IgG 
preparations pooled from patient cohorts (n=26-27) show that pathological autoantibodies are 
present in the wider population of patients with persistent CRPS, and that patients with more 
severe pain have higher effective autoantibody titres than patients with moderate pain intensity. 
Electrophysiological investigation of skin-nerve preparations from mice treated with CRPS IgG 
from a single patient identified both a significantly increased evoked impulse activity in A- and 
C-nociceptors, and an increased spontaneous impulse rate in the intact saphenous nerve. Our 
results show that painful hypersensitivity in persistent CRPS is maintained by autoantibodies, 
which act by sensitizing A- and C-nociceptors. 
 
Keywords: Complex Regional Pain Syndromes; nociceptors; Passive transfer; IgG; mice 
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Introduction 
Complex regional pain syndrome (CRPS) is a post-traumatic condition typically confined to a 
single limb. CRPS is characterized by pain of disproportionate intensity and duration compared 
to that expected from the clinical time course of the initial injury or trauma, but the etiology and 
pathophysiological basis of CRPS are incompletely understood[6,22,37,39,53]. Distal limb 
fractures are the most common triggers of CRPS, but the severity of CRPS is independent of the 
initiating trauma, and apparently trivial insults can lead to CRPS[43,61]. The affected limb 
typically exhibits several characteristic abnormalities, including increased sensitivity to both 
normally innocuous and painful stimuli, skin discoloration, fluctuating temperature asymmetry 
(compared to the uninjured limb), swelling, sudomotor alterations, and trophic changes to skin, 
hair and nails. Pain is, however, the dominant symptom and CRPS is not associated with tissue 
destruction[9,53]. No diagnostic tests exists for CRPS, and patients are diagnosed based on 
clinical symptoms and signs[10,23,30]. Most patients recover spontaneously, but 15-20% of 
patients develop persistent severe pain, which may last for life and is associated with an 
exceptionally low quality of life, even when compared to other chronic pain conditions[40,59]. 
The characteristic autonomic abnormalities seen early in the course of CRPS typically normalize 
in patients with long-standing disease, whereas pain, as well as sensory and motor abnormalities 
may remain. This has led to suggestions that persistent CRPS is sustained by abnormal central 
nervous system plasticity[46].  
Earlier investigations have demonstrated that administration of IgG from patients with persistent 
CRPS (>1 year duration) to mice reduced spontaneous rearing in freely moving mice[28]. When 
IgG transfer was combined with a paw incision as an experimental insult, a transiently enhanced 
postsurgical swelling and mechanical hypersensitivity in the injured paw was observed[27]. 
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Later studies demonstrated that immunoglobulins of other isotypes were inactive, since transfer 
of IgG-depleted serum was without effect[55]. These results indicate that IgG autoantibodies are 
central for the genesis and maintenance of pain and painful hypersensitivities in persistent CRPS.   
Importantly, the underlying neuronal mechanisms and sites of action responsible for pain have 
not been identified.   
In this study, we have performed a detailed behavioral and electrophysiological investigation of 
painful sensory abnormalities in the passive transfer-trauma model of CRPS (tCRPS[55]) and 
identified peripheral sensitization of nociceptors as a major mechanism by which autoantibodies 
produce pain in CRPS. 
 
Materials and Methods 
Study Design 
We examined the impact of a paw incision in combination with administration of serum IgG 
purified from healthy control subjects or CRPS patients on mouse nociception both in vivo and 
ex vivo. 
Research subjects 
The main immunoglobulin donor was a 40 year old female who had CRPS of 9 years’ duration 
in a lower limb and a high average pain (9-10/10 on a 11-point numeric rating scale (NRS) with 
10=the worst pain imaginable) and had been offered clinical plasma exchange treatment on 
compassionate grounds[2,26]. She had signs in all four Budapest diagnostic categories[30] and 
alternative causes for her pain had been excluded by a pain specialist, a consultant 
rheumatologist and a consultant neurologist. This patient clinically exhibited strong pain to mild 
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pressure over the painful area (i.e. mechanical hyperalgesia, the most common sensory 
abnormality in persistent CRPS[23,32]), whereas she had little or no pain to light touch; she 
reported that ambient temperatures below room temperature and also temperatures above 
approximately 24°C would increase her pain. Waste plasma from the first exchange treatment 
was secured with her consent and was stored frozen – the local Ethics committee confirmed that 
the use of human waste tissue did not require ethical permission. She received three plasma 
exchange treatments over 5 days through a central venous line, but unfortunately the treatment 
had to be ceased thereafter as a consequence of clotting around the tip of the line. She reported 
no pain relief following this treatment; in line with earlier observations indicating that 7-8 
exchange treatments over 3 weeks may be required before meaningful pain relief occurs in this 
condition[2,26,49]. 
For experiments on pooled IgG, serum samples were randomly selected from an anonymized list 
of 111 stored frozen samples (-80°C) and stratified according to either moderate (NRS 5.0-7.0, 
26 patients) or high (NRS 7.3-9, 27 patients) baseline pain intensity,. The serum samples were 
provided by participants in the recently-completed LIPS-trial[25]. The LIPS study-inclusion 
criteria were patients with persistent CRPS of between 1 and 5 years’ duration, fulfilling 
international research criteria for the diagnosis of CRPS[30], who had an average pain intensity 
at baseline of at least 5/10. Ethical permission and individual consent for the use of these sera for 
the purpose of autoantibody research is available (12/EE/0164, East of England). 
 
IgG purification 
IgG was purified as described previously[55], using protein G beads (Sigma-Aldrich, 
Gillingham, UK). Briefly, serum was diluted 1:3 with Hartmann’s solution, passed through a 
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protein G column, and the bound IgG was eluted using 100 mM glycine pH 2.3, the pH was 
adjusted to 7.4 using 1 M Tris pH 8.  The preparation was then dialyzed overnight at 4°C in 
Hartmann’s solution using a 10 kDa dialysis membrane (Fisher Scientific, Loughborough, UK). 
The concentration of IgG present after dialysis was determined using a modified Lowry assay 
(DC protein assay, BioRad, Hemel Hempstead, UK) and adjusted by dilution with Hartmann’s 
solution or by dialysis against a sucrose solution (Sigma-Aldrich). Finally, the IgG solution was 
sterile filtered using syringe-driven 0.2 µm filter units (Millipore, Watford, UK), stored at 4°C 
and used within 3 months. 
 
Animals 
Surgical procedures and behavioral experiments were carried out according to the U.K. Home 
Office Animal Procedures (1986) Act. All procedures were approved by the King’s College 
London Animal Welfare and Ethical Review Body and conducted under UK Home Office 
Project Licenses PPL 70/7510 and PF0C9D185. Experiments were performed on female 
C57Bl/6J mice (8– 10 weeks old) obtained from Envigo UK Ltd., Bicester, UK, housed in a 
temperature-controlled environment with a 12h light/dark cycle and with access to food and 
water ad libitum. Mice were injected intraperitoneally with Hartmann’s solution containing 0.8-
16mg of IgG from either healthy control subjects or CRPS patients on 4 consecutive days, or as 
indicated. 
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Plantar Incision  
On the day of the second IgG injection, a 5 mm long midline incision was made through the 
plantar skin fascia starting 2 mm from the heel and extending towards the toes, using aseptic 
techniques. The underlying plantar muscle was elevated with curved forceps and incised 
longitudinally, leaving the muscle origin and insertion intact[8]. The skin incision was then 
closed using sutures (Mersilk 7/0) and the animals were housed on paper bedding for the first 3 
days post-surgery. 
Behavioral studies 
Before any nociceptive testing, mice were kept in their holding cages to acclimatize (10-15 min) 
to the experimental room. Mice were randomized between cages and the experimenter blinded to 
their treatment. 
The Randall-Selitto paw-pressure test was performed using an Analgesymeter (Ugo-Basile, 
Italy). The experimenter lightly restrained the mouse and applied a constantly increasing 
pressure stimulus to the dorsal surface of the hind paw using a blunt conical probe. The 
nociceptive threshold was defined as the force in grams at which the mouse withdrew its 
paw[44]. A force cut-off value of 150 g was used to avoid tissue injury. 
Tactile sensitivity was assessed using von Frey filaments (0.008-2 g) according to Chaplan’s up-
down method[12]. Animals were placed in a Perspex chamber with a metal grid floor allowing 
access to their plantar surface and allowed to acclimatize prior to the start of the experiment. The 
von Frey filaments were applied to the plantar surface of the hind paw with enough force to 
allow the filament to bend, and held static for approximately 2-3 s. The stimulus was repeated up 
to 5 times at intervals of several seconds, allowing for resolution of any behavioral responses to 
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previous stimuli. A positive response was noted if the paw was sharply withdrawn in response to 
filament application or if the mouse flinched upon removal of the filament. Any movement of the 
mouse, such as walking or grooming, was deemed an unclear response, and in such cases the 
stimulus was repeated. If no response was noted a higher force hair was tested and the filament 
producing a positive response recorded as the threshold. 
Thermal sensitivity was assessed using a hot- and cold-plate (Ugo Basile, Milan). Paw 
withdrawal latencies were determined with the plate set at a chosen temperature (50 °C for hot-
plate and 10 °C for cold-plate tests). The animals were lightly restrained (scruffed) and each hind 
paw in turn was placed onto the surface of the plate[1,21]. The latency to withdrawal of the paw 
was taken as the endpoint and recorded for the ipsilateral and the contralateral paw. A maximum 
cut-off of 30 seconds was used for each paw. 
Human IgG ELISA 
Human IgG ELISA Kit ab195215 (Abcam, Cambridge, UK) was used to measure the transferred 
human-IgG concentration in mouse plasma. Plasma was prepared from whole blood using 
heparin treated tubes and stored at -20°C until use according to the provided instructions from 
the manufacturer. 
Skin-nerve recording 
Mice were killed by cervical dislocation and the hind paw was shaved prior to dissection of the 
isolated skin-nerve preparation. The saphenous nerve and the shaved skin of the hind limb were 
placed in a recording chamber at 32 °C. The chamber was perfused with a gassed (95% O2 and 
5% CO2) prewarmed synthetic interstitial fluid (SIF): 108mM NaCl, 3.5mM KCl, 0.7mM 
MgSO4, 26.2mM NaCO3, 1.65mM NaH2PO4, 1.53mM CaCl2, 9.6mM sodium gluconate, 
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5.55mM glucose and 7.6mM sucrose. The skin was placed inside up (corium side up) and pinned 
down using insect pins (0.2 mm diameter) in the organ bath to allow access to the receptive 
fields. The saphenous nerve was fed through a small gap from the organ bath to an adjacent 
recording chamber and placed on a mirror platform. The desheathed saphenous nerve was 
covered with paraffin oil for electrical isolation and either whole nerve or dissected fine nerve 
filaments were placed on a fine gold wire-recording electrode[45,63]. 
Conduction velocity 
The saphenous nerve was divided into progressively thinner filaments until a single unit could be 
isolated in response to mechanical stimulation of the receptive field with a glass rod. Identified 
units were electrically stimulated with brief, 1ms pulses (Digitimer DS2, Digitimer Ltd, Welwyn 
Garden City, UK) and the action potential latency was used to determine the conduction velocity 
and to categorize units as Aβ (>10m/s), Aδ (1.2-10m/s) or C-fibers (<1.2m/s).  
Mechanical stimulation 
A computer-controlled stimulating probe, equipped with a force transducer, was used to deliver 
mechanical stimuli to the most sensitive spot of a receptive field (Axolent UG, Erlangen, 
Germany). The mechanical threshold for each unit was then determined iteratively by applying a 
series of 2s mechanical force steps. The mechanical threshold was determined as the force 
required to elicit at least two action potentials. The adaptation properties of single units were 
characterized by stimulation with 10s force step challenges in the range 0.5-20g with a 2 min 
recovery period between challenges. Aβ units that fired briefly during the application and 
removal of the force were considered rapidly adapting (RA), and those that sustained firing 
throughout the challenge were classified as slowly adapting (SA). Low-threshold Aδ units with a 
transient action potential discharge pattern (on and off) were identified as D-hair fibers. The 
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coding properties of Aδ and C-fibers were additionally examined using a series of force ramp 
stimuli (0.5-20g, 15s duration, with a 2 min recovery period between challenges). Recording and 
analysis were done using Spike 2 (Cambridge Electronic Design, Cambridge, UK). 
Statistical analysis 
Data are expressed as mean ± SEM of the number of animals or nerve fibers indicated (n). 
Behavioral data were analyzed using unpaired t-test, Mann-Whitney U test (when Levene’s test 
of equality of variances p<0.05) or ANOVA (followed by Tukey’s, Dunnett’s or Holm-Sidak’s) 
as appropriate. Statistical tests were performed in SPSS 24 (IBM), Statistica (Tibco), SigmaPlot 
14, or Excel 2016 (Microsoft). 
 
Results  
Passive transfer of CRPS pain (tCRPS) 
We examined the behavioral phenotype of tCRPS by comparing mice subjected to a paw incision 
alone with mice that additionally received IgG from a CRPS patient or a healthy control subject 
(HC) on 4 consecutive days (8mg by intraperitoneal injection), starting the day before paw 
incision. In these experiments, we used IgG from a patient who had CRPS with high average 
pain scores (9-10 on a 11 point numerical rating scale), since this may indicate a high titre of 
pathogenic autoantibodies[16]. Following the paw incision, mice in all treatment groups 
developed hypersensitivity to noxious mechanical stimulation in the paw pressure test (Fig. 1, A 
and B), and to tactile stimulation with von Frey filaments (Fig. 1, C and D). Mice that had been 
subjected to a paw incision alone or in combination with IgG from control subjects recovered 
fully from the postsurgical mechanical hyperalgesia measured by paw pressure thresholds within 
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three days, whereas tCRPS mice retained the maximal level of hypersensitivity without signs of 
recovery during the assessment period. In contrast, all three treatment groups recovered from the 
postoperative tactile allodynia assessed with von Frey filaments at a similar rate. The mechanical 
sensitivities of the uninjured, contralateral paws were unaffected, or minimally affected (Fig. 1, 
B and D), confirming that both circulating CRPS IgG and trauma are required for the onset of 
tCRPS.  
The donor-patient reported increased sensitivities to cold and heat, as is common in CRPS 
[23,32], and we therefore also assessed thermal nociception using cold and hot plate assays. 
Mice treated with CRPS IgG progressively developed significant cold and heat 
hypersensitivities, associated with a significant contralateral sensitization, whereas the other 
treatment groups displayed less marked changes and recovered quickly (Fig. 1E-H). Our 
observations indicate that CRPS IgG administration dramatically exacerbates and prolongs 
painful hypersensitivities produced by a minor surgical trauma and accurately translates the 
sensory abnormalities observed in the donor patient to mice. 
 
Dose-dependence of CRPS IgG passive transfer  
To determine the dose requirements for successful passive transfer of sensory abnormalities, we 
administered patient IgG at doses between 0.8 to 8 mg on 4 consecutive days, with one group of 
mice only receiving two injections of 8 mg. Administration of 8 mg CRPS IgG only on the first 
two days was without effect compared to HC IgG (Fig. 2AB). Lower doses of CRPS-IgG 
(4x0.8mg, 4x4mg) induced no or only minimal detectable abnormalities to mechanical stimuli 
(Fig. 2A) whereas administration of 4mg CRPS IgG per day produced an intermediate level of 
cold hypersensitivity for the duration of the experiment (Fig. 2B). We monitored the behavioral 
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profile of all groups for a week after the incision but extended this to two weeks for mice treated 
with 4x8mg CRPS IgG (and the corresponding HC group), since this was the only treatment 
group that displayed mechanical hypersensitivity. In the 4x8 mg group, hypersensitivities to 
noxious mechanical (Fig. 2A) and cold stimulation (Fig. 2B) were maintained for at least two 
weeks. The contralateral paw displayed a transiently and marginally increased sensitivity to 
noxious cold or mechanical stimulation in the 4x8mg group, which resolved by day 6 (Fig. 2C, 
D). 
To determine whether the circulating human IgG concentration was correlated with the observed 
behavioral phenotype, we measured the plasma concentration of human IgG by ELISA on days 
3, 8 and 13 after incision in mice treated with HC-IgG or CRPS-IgG. On the day of the last 
injection (day 3) the plasma concentration of human IgG was 19±9 mg/ml, similar to that 
normally found in human subjects (6-16mg/ml). At later time points (day 8 and 13) the 
circulating human IgG concentration was negligible (2.3±0.3 and 2.6±0.3 ng/ml). Collectively, 
these results show that induction of the tCRPS sensory phenotype requires doses similar to those 
used for passive transfer of other autoantibody mediated neurological conditions, such as 
myasthenia gravis[14,56,57].  
 
The tCRPS phenotype reflects the donor patients’ pain intensities 
To determine whether the sensory phenotype observed in tCRPS mice is related to the donor-
patients’ pain intensities, we next compared the effects of IgG preparations pooled from patients 
from the LIPS trial[25].  Patients were stratified according to their baseline pain intensities 
within moderate (n=26; 6.0±0.8 mean±SD; range 5.0-7.0) and high (n=27; 8.3±0.4; range 7.3-
9.5; table 1) ranges on a 11-point numerical rating scale (NRS) [7]. Pooled IgG (4x8mg) from 
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patients with severe pain, but not from patients with moderate pain, produced significant 
mechanical hypersensitivity 7 days after the incision, when the postsurgical hypersensitivity seen 
in mice that were only subjected to a paw incision had recovered fully (Fig. 3A, see Fig. 2A). 
This observation indicates that the degree of mechanical hyperalgesia in tCRPS mice reflects the 
donor patients’ spontaneous pain intensities. The different effects of IgG from patients with 
moderate or high pain may further suggest that target heterogeneity or autoantibody titre 
influences symptom severity as in other autoantibody-medicated painful conditions[33]. 
Alternatively, autoantibodies may play no role in the group of patients with only moderate pain. 
To investigate this latter possibility further, we examined the effect of a larger dose (16mg/day, 
Fig. 3B) of pooled IgG from patients with moderate pain intensity and found that this larger dose 
produced significant hypersensitivity compared to HC IgG (16mg/day). Interestingly, this effect 
was more transient than that observed in mice treated with IgG (8mg) from patients with higher 
pain intensity. As the contributions of IgG from individual patients were diluted in these pooled 
IgG samples (26-27 patients), our results strongly suggest that autoantibodies are universally 
responsible for maintaining pain in patients with persistent CRPS. The time required for mice to 
recover from tCRPS appear variable, with full recovery observed within 2 weeks for the pooled 
IgG preparations (Fig. 3B), but only a partial recovery with the main patient donor over the same 
period (Fig. 2). 
 
CRPS IgG induces spontaneous impulse generation in skin-saphenous nerve preparations 
Ectopic sensory afferent impulse discharge generates spontaneous pain and paraesthesias in 
rodents and human patients[50,51,60]. Persistent spontaneous pain is a hallmark of CRPS, and 
we therefore recorded the activity of the intact saphenous nerve, before splitting the nerve into 
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thin filaments for studies of single units described below. In this configuration, IgG from the 
main patient donor significantly increased the spontaneous ongoing impulse rate (7.1±2.4Hz) 
compared to preparations from naïve (0.9±0.4Hz), incision only (1.4±0.4Hz) and HC IgG 
(1.4±0.5Hz) treated mice (p<0.01, Kruskal-Wallis test, Fig. 4, preparations harvested 3 days after 
incision).  This demonstration of enhanced ectopic activity in an in vitro preparation isolated 
from the central nervous system suggests that CRPS-IgG exerts a peripheral pathogenic and 
proalgesic effect. 
Electrophysiological investigations of mechanosensitive sensory afferents 
Mechanical hypersensitivity is an almost ubiquitous sensory abnormality in patients with 
persistent CRPS[32], and a prominent characteristic of the tCRPS phenotype (Figs. 1-3), which 
suggests that CRPS IgG alters the function of mechanosensitive nociceptors. Therefore, we 
examined the function of mechanosensitive single units in skin-saphenous nerve preparations. 
This approach allowed us to quantify the afferent action potential responses evoked by 
mechanical stimulation of the receptive fields in their intact anatomical and physiological 
context. We determined the mechanical activation threshold, conduction velocity and temporal 
response profiles of Aδ- and C-mechanonociceptors (AM and CM), as well as of the low 
threshold mechanosensitive fiber types, Aβ- (RA and SA), and D-hair Aδ-fibers. We did not 
observe a significant spontaneous impulse activity in the recorded single units. 
A-mechanonociceptors 
Aδ-mechanonociceptor (AM) fibers in preparations from tCRPS mice displayed a modestly 
reduced mechanical force threshold for activation (Levene’s p<0.05, Mann-Whitney p=0.056, 
Fig. 5A), but an unaltered conduction velocity compared to preparations from mice only 
subjected to a paw incision (Table 2). Application of mechanical step- or ramp-shaped force 
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stimuli (from 0.5 to 20g, applied for a duration of 10 and 15s, respectively) demonstrated that 
AM fibers in tCRPS preparations responded with a higher impulse rate throughout the range of 
forces used (Fig. 5B-G). Analysis of the impulse pattern evoked by a 5g force step challenge, 
revealed that tCRPS AM fibers responded with a markedly increased impulse rate, but with a 
very similar temporal profile compared to that observed in preparations from mice that were not 
treated with IgG (Fig. 5D, F). AM-fibers encode increasing mechanical force with a 
corresponding linear increase in impulse frequency[36], and our results show that this force-
impulse relationship in response to ramp stimuli is significantly steeper in AM fibers from 
tCRPS mice than in non-IgG treated mice (Fig. 5E, G). The combination of a steeper force-
impulse rate relationship, and a relatively minor force threshold reduction suggests that both 
transduction and excitability processes are sensitized by CRPS IgG in tCRPS mice (Fig. 5A, E). 
In keeping with the steeper force-impulse relationship observed in tCRPS AM fibers, the 
maximal impulse discharge rates evoked by either a 20g force step (Fig. 5H) or a force ramp to 
20g (Fig. 5I) were increased significantly, compared to AM fibers in preparations from mice that 
were only subjected to a paw incision. 
C-mechanonociceptors 
The mechanical threshold for activation of C-mechano-nociceptor (CM) fibers was significantly 
reduced in preparations from tCRPS mice, compared to preparations from mice that had only 
undergone a paw incision (Fig. 6A). The force thresholds of single units in the control group 
were distributed through the range 0-7g, whereas all units in tCRPS preparations responded at 
forces below 3g. The C-fiber conduction velocity did not differ significantly between the 
treatment groups (table 2). Analysis of the response pattern evoked by a series of force steps and 
ramps identified a significantly increased impulse rate in tCRPS CM fibers at the highest forces 
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used (Fig. 6B-G, Levene’s, p<0.05, Mann-Whitney, p<0.05). The temporal distribution of action 
potentials during stimulation with mechanical force appeared unchanged, which is similar to our 
observations in AM-fibers (Fig. 6F, G). The maximal impulse discharge rate was increased in 
preparations from tCRPS mice compared to paw incision alone (Fig. 6H, I). 
 
Low threshold mechanosensitive A-fibers 
We assessed the functional impact of tCRPS on the major classes of low-threshold 
mechanosensitive afferent fibers; slowly adapting Aβ- (SA), rapidly adapting Aβ- (RA) and D-
hair (DH) Aδ-fibers. Consistent with the absence of tactile allodynia in tCRPS mice in vivo (see 
Fig. 1C), the conduction velocities and mechanical force activation thresholds of SA, RA and 
DH fibers were indistinguishable in preparations from the two treatment groups (Table 2, Fig. 
7A-F). In good agreement with earlier characterizations [36], mechanically evoked responses in 
control RA and SA units did not encode forces above 5g with an increasing number of action 
potentials. The impulse discharge rates of RA and SA fibers did not differ between treatment 
groups (Fig. 7B, D). Similarly, we could not distinguish between the numbers of action 
potentials generated in response to force steps in DH fibers in preparations from tCRPS and 
incision only mice (Fig. 7E, F). 
 
Discussion  
Here we demonstrate that administration of IgG from patients with persistent CRPS, in 
combination with a minor experimental insult, transfers persistent mechanical, as well as thermal 
sensory abnormalities from donor patients to mice (‘tCRPS’). We further show that the degree of 
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transferred sensory abnormalities correlates both with the transferred IgG dose, and the 
respective donor-patients’ subjective pain intensities. Electrophysiological investigations of skin-
saphenous nerve preparations from mice treated with IgG from a typical patient-donor 
demonstrate a markedly increased stimulus-evoked discharge rate in A- and C-
mechanonociceptor single units, accompanied by a reduction in the mechanical response 
threshold.  In contrast, low-threshold A-fibers were unaffected by CRPS patient IgG.  The single 
nerve fiber properties thus reflect both this donor patient’s clinical experience and the transferred 
behavioral phenotype observed in mice.  We studied saphenous single units with receptive fields 
in the uninjured dorsal hind paw skin, rather than the incised plantar skin. The functional 
abnormalities observed in these nociceptors are thus not directly explained by the postsurgical 
hypersensitivity seen in sural and tibial single units innervating the incised plantar skin [3,8], but 
are consistent with the more generalized regional pain seen in patients who develop CRPS after 
injury[6,53].   
After administration, IgG distributes into the interstitial fluid of tissues, and its pharmacokinetic 
behavior can typically be described using a two-compartment model, with a rapid, first-order 
elimination from circulation, and a slower second-order component clearing IgG from tissues 
[48].  The behavioral phenotype of tCRPS is stable for at least two weeks, a time course that is 
consistent with the observed terminal half-life of human IgG in mice[48,58].   
Although most of the results presented here were collected using IgG from a single patient, IgG 
pooled from 27 patients with high baseline pain intensity demonstrated a similar degree of 
mechanical hypersensitivity in vivo to that observed with IgG from the main donor.  In 
comparison, IgG from 26 patients with moderate pain intensity, produced a more transient 
hypersensitivity, and required administration of larger doses.  Although we cannot estimate the 
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fraction of CRPS patients with sensitization-supporting IgG, our results with the pooled samples 
are consistent with such antibodies being found in a substantial portion of chronic CRPS 
patients. If a substantial proportion of CRPS patients with high pain intensity lack 
autoantibodies, we would have expected a sharply reduced behavioral response in experiments 
with pooled IgG from this group of patients. The reduced activity of IgG from patients with 
moderate pain severity suggest a correlation between the reported pain intensity and the effective 
serum concentration of autoantibodies. These conclusions are consistent with previous studies of 
IgG from a number of patients with longstanding severe CRPS, all of which produced 
mechanical hypersensitivity in the tCRPS model[31,55].  Importantly, the increased spontaneous 
and evoked action potential discharge rate observed here in ex vivo skin-nerve preparations 
demonstrates that patient IgG produce nociceptor hyperexcitability.   
CRPS has very recently been reported to be associated with an expansion and activation of 
memory T-cells[47] and there is evidence of an altered profile of tissue resident cutaneous T-
cells in the limb affected by CRPS[5,41].  It is not yet clear how the initial trauma contributes to 
the subsequent autoantibody mediated pathology in CRPS [43]. It is possible that the injury 
induces production of neoantigens and that the plasma extravasation, produced around the 
trauma at a time when the blood nerve barrier may be compromised[52], facilitates access of IgG 
to the affected area.  Intriguingly, studies of the tibial fracture, cast immobilization experimental 
model of CRPS have demonstrated that mice in this model reproducibly develop long-lasting, 
painful sensory abnormalities and vascular dysregulation in the injured limb, very similar to the 
acute phase of CRPS[29,38]. This CRPS-like experimental condition is produced by IgM-
mediated autoimmunity, which can be transferred between mice [29] and it is associated with 
reactivity against proteins that are upregulated or undergo a cellular redistribution after the 
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fracture[54]. Clinical observations suggest that early immobilization after fractures increase the 
risk of CRPS in humans[13,19], and results from the tibial fracture, cast immobilization mouse 
model may indicate that IgM mediated autoimmunity is responsible for the onset and early phase 
of CRPS.  
An emerging body of evidence indicates that autoantibodies are the primary pathological agents 
responsible for pain in some painful disorders other than CRPS [15,24]. Autoantibodies that 
target citrullinated proteins produce pain in rheumatoid arthritis (RA) by stimulating IL-8 release 
from osteoclasts, even when inflammation is clinically well-controlled [11,62]. Serum-IgG from 
patients suffering from rare painful neurological autoimmune disorders targeting the voltage-
gated potassium channel complex (VGKCC, specifically CASPR2) elicit painful 
hypersensitivities upon transfer to mice[16]. CASPR2 autoantibodies cause pain by reducing the 
surface expression of Kv1 channels and enhancing the activity of D-hair Aδ-fibers. These earlier 
mechanistic investigations thus demonstrate that autoantibodies can cause pain either indirectly, 
by stimulating release of proalgesic mediators from other cells[11], or by directly affecting the 
activity of sensory neurons[16]. Importantly, VGKCC autoantibodies have not been observed in 
CRPS patients[4,33,42], and we did not detect functional abnormalities in D-hair fibers in tCRPS 
mice, highlighting that VGKCC autoantibodies generate pain by mechanisms that are distinct 
from those that are engaged by CRPS IgG. 
The proteins and processes by which autoantibodies in persistent CRPS produce pain and 
hypersensitivity remain unknown, but earlier investigations have demonstrated that a subset of 
patients produce IgG that recognize epitopes on autonomic neurons and SH-SY5Y cells[35].  
Further studies identified specific binding to M2 muscarinic as well as to β2- and α1 
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adrenoreceptors[18,34], but the relevance of these receptors for CRPS pain and autonomic signs 
is not yet clear. 
Here, we identified an increased spontaneous impulse rate in the intact saphenous nerve in skin-
saphenous nerve preparations from tCRPS mice. Although it is not possible to determine which 
fiber types are responsible for the heightened ectopic activity in our preparations, such ectopic 
discharge is likely to be responsible for spontaneous pain and paraesthesias[50,51,60]. We 
further identified an increased responsiveness to mechanical stimulation of AM- and CM 
nociceptors characterized both by a reduced mechanical threshold and by an increased impulse 
discharge rate in response to supra-maximal stimulation.  It is likely that this increased peripheral 
drive gives rise to spinal sensitization, which would be consistent with the recent finding that 
spinal mechanisms involving interleukin-1β are engaged in tCRPS[31].  Upregulation of spinal 
interleukin-1β has previously been demonstrated in experimental models of neuropathic and 
arthritic pain[17,20]. 
The results presented here support the use of immune therapies, such as plasmapheresis[2] or B-
cell ablation, to reduce autoantibody titre in patients with persistent CRPS. The variable time 
required for mice to recover from tCRPS suggests that patients may need to undergo relatively 
extended treatment periods to benefit from reduced IgG titres, consistent with the available data 
from trials with therapeutic plasma exchange[26].  
Our results demonstrate that IgG autoantibodies from CRPS patients generate painful 
hypersensitivities by increasing the activity of peripheral nociceptors and this new information 
may guide future attempts at identifying targets for interventions.  
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FIGURE LEGENDS 
Fig. 1. CRPS IgG produce polymodal hypersensitivities in mice. Administration of CRPS 
patient IgG (8mg, i.p. on days -1 to 2), prolonged and exacerbated the ipsilateral mechanical (A), 
cold (E) and heat (G) hypersensitivity produced by a paw incision (on day 0) compared to mice 
treated with IgG from healthy control subjects or no IgG. The sensitivity to stimulation with von 
Frey filaments was unaffected by CRPS IgG (C). The contralateral, uninjured paw displayed a 
much less marked hypersensitivity in all four tests (B, D, F, H). Data are mean ± SEM of n=6. 
*p < 0.05, **p < 0.01, ***p < 0.001, One-way ANOVA, followed by Tukey's, CRPS compared 
to HC IgG group. †p<0.05, ††p<0.01, †††p<0.001, One-way ANOVA, compared to naïve values 
before surgery and injection, Dunnett’s post-hoc test. 
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Fig. 2. CRPS IgG induced dose-dependent and sustained hypersensitivities. Effect of 
different dose regimens of serum IgG from CRPS patient compared to HC IgG on ipsilateral (A) 
and contralateral paw (B) withdrawal thresholds to mechanical pressure, and (C) ipsilateral and 
(D) contralateral paw withdrawal latencies to noxious cold (10°C). IgG was administered on 
days -1 to 2 (4 injections) or days -1 and 0 (2x8mg), and paw incisions were performed on day 0. 
Data are mean ± SEM of n=6. Data points from all groups and time points were tested by one-
way ANOVA followed by Holm-Sidak’s post-hoc: *p < 0.05, **p < 0.01, ***p < 0.001, vs HC 
IgG. 
Figure 3. The phenotype of tCRPS mice is related to the pain intensity of CRPS patient IgG 
donors. (A) Ipsilateral paw withdrawal thresholds to paw pressure before and 7 days after paw 
incision (4 days after the last IgG injection), in mice injected with IgG (8mg) pooled from either 
healthy control subjects (HC), CRPS patients with moderate pain intensities, or CRPS patients 
with high pain intensities. (B) Paw withdrawal threshold of mice treated with 4x16mg of IgG 
from HC IgG or CRPS patients with moderate pain intensities, or 4x8mg of IgG from patients 
with high pain intensities. n=5-6. ANOVA with Tukey’s post-hoc (A, B): *p < 0.05, **p < 0.01, 
***p < 0.001, vs HC IgG group. One-way ANOVA, pre and post-surgery comparison using 
Dunnett’s post-hoc test (A). ††† p < 0.001. 
Figure 4. CRPS IgG increases the spontaneous impulse rate in skin-saphenous nerve 
preparations. (A) Typical examples of spontaneous activity recorded in skin-nerve preparations 
from naïve mice, mice only subjected to a paw incision, or subjected to a paw incision in 
combination with IgG from HC or CRPS patient. (B) Frequency of spontaneous activity recorded 
in the intact saphenous nerve. Each data point represents one preparation/animal. **p < 0.01, 
Kruskal-Wallis. 
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Figure 5. CRPS IgG sensitizes AM fibers. (A) Mechanical response thresholds of AM fibers in 
preparations from tCRPS mice and mice that only underwent incision. (B) Example traces of 
AM fiber action potentials evoked by a 5g force step and (C) a force ramp stimulus to 10g. The 
temporal impulse pattern is displayed in histograms (lower panel). (D-E) The mean number of 
action potentials (AP) evoked by force step (D) and ramp (E) stimuli (0.5g-20g) in preparations 
from incision only compared to tCRPS mice; the linear regression of the force-impulse 
relationship with 95% confidence interval is shown in shaded pink/gray. (F) The mean impulse 
pattern of AM fibers during 10s constant 5g force simulation and (G) 15s ascending force of 10g 
(means calculated from all fibers presented in D, E). (H) Peak firing frequency (events/s) in 
incision compared to CRPS groups for 5g ramp stimulation and (I) 10g ramp stimulation. Data 
are mean±SEM or individual data points. Levene’s test p<0.05; Mann-Whitney U-test: *p < 
0.05, **p < 0.01, CRPS group comparison with incision group. 
Fig. 6. CRPS IgG sensitizes CM fibres. (A) Mechanical response thresholds of CM fibers in 
preparations from tCRPS mice and mice that only underwent incision. (B-C) Example traces of 
C-fiber action potentials evoked by a 20g force step (B), and a force ramp (C) stimulus to 20g. 
The temporal impulse discharge frequencies are shown as histograms (events/s). (D-E) Mean 
number of action potentials (AP) evoked by (D) step stimuli of (0.5g-20g) and (E) ramp stimuli 
in incision and CRPS mice. The force-impulse relationship is indicated by linear regression, with 
the 95% confidence interval shaded. (F-G) Mean pattern of action potential rate in CM-fibers in 
response to (F) a 10s constant 20g force application and (G) a 15s force ramp challenge to 20g. 
(H-I) Peak firing frequency (events/s) in incision versus CRPS groups for 20g force step (H) and 
ramp (I) stimuli. Data are mean±SEM. *p < 0.05, ***p<0.001, t-test (A, B, H, I) or Mann-
Whitney (following Levene’s test p<0.05), CRPS group comparison with incision group. 
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Fig. 7. Low threshold mechanosensitive Aβ and DH fibers are unaffected by CRPS IgG. 
Mechanical response thresholds determined by 2s force step challenges (A, C, E) and mean 
number of action potentials (AP) evoked by 10s, 0.5g-20g force steps (B, D, F) in preparations 
from tCRPS mice and mice that were subjected to paw incision alone. Slowly adapting Aβ fibers 
(A, B), rapidly adapting Aβ fibers (C, D) and DH fibers (E, F). Data are mean ± SEM. Mann-
Whitney (following Levene’s test p<0.05), tCRPS compared to incision only. 
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Table 1. Characteristics of patient IgG donors. 
 Moderate pain (n=26) High pain (n=27) 
Age (years, average±SD) 43±14 41±10 
CRPS duration (years, median 
(range)) 
3 (1-5) 3 (1-5) 
% female 54% 77% 
Baseline pain intensity 
(average) 
6.0 ±0.8 (SD, range 5.0-6.9) 8.3 ±0.4 (SD, range 7.3-
9.5) 
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Table 2. Conduction velocity of the different fibers from incision only and tCRPS preparations. 
Data are mean ± SEM. AM, CM and RA-Aβ units were tested with Mann-Whitney, whereas SA-
Aβ and D-hair were tested with a t-test.  
Fiber type  
Incision only 
conduction 
velocity (m/s) 
tCRPS 
conduction 
velocity (m/s) 
P values 
RA-Aβ 12. 0±0.6 (n=16) 15.7±2.0 (n=12) 0.07 
SA-Aβ 12.9±0.7 (n=14) 13.2±0.5 (n=13) 0.85 
D-hair 6.3±0.7 (n=10) 7.2±0.8 (n=9) 0.39 
AM1 7.3±0.7 (n=17) 6.2±0.6 (n=23) 0.28 
CM2 0.52±0.1 (n=14) 0.78±0.1 (n=13) 0.07 
1Aδ- mechanonociceptor, 2C-mechanonociceptor 
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